Mitochondrial Proteases as Emerging Pharmacological Targets

Author(s): Lara Gibellini, Sara De Biasi, Milena Nasi, Anna Iannone, Andrea Cossarizza, Marcello Pinti

Journal Name: Current Pharmaceutical Design

Volume 22 , Issue 18 , 2016

Become EABM
Become Reviewer
Call for Editor


The preservation of mitochondrial function and integrity is critical for cell viability. Under stress conditions, unfolded, misfolded or damaged proteins accumulate in a certain compartment of the organelle, interfering with oxidative phosphorylation and normal mitochondrial functions. In stress conditions, several mechanisms, including mitochondrial unfolded protease response (UPRmt), fusion and fission, and mitophagy are engaged to restore normal proteostasis of the organelle.

Mitochondrial proteases are a family of more than 20 enzymes that not only are involved in the UPRmt, but actively participate at multiple levels in the stress-response system. Alterations in their expression levels, or mutations that determine loss or gain of function of these proteases deeply impair mitochondrial functionality and can be associated with the onset of inherited diseases, with the development of neurodegenerative disorders and with the process of carcinogenesis. In this review, we focus our attention on six of them, namely CLPP, HTRA2 and LONP1, by analysing the current knowledge about their functions, their involvement in the pathogenesis of human diseases, and the compounds currently available for inhibiting their functions.

Keywords: Mitochondria, mitochondrial proteases, CLPP, LONP1, HTRA2, inhibitors.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 04 May, 2016
Page: [2679 - 2688]
Pages: 10
DOI: 10.2174/1381612822666160202130344
Price: $65

Article Metrics

PDF: 95
HTML: 12
PRC: 2